Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.
Cancer syndromes
Colorectal cancer
Early‐onset
Histone modifiers
Microsatellite instability
Tumor mutational burden
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
27
02
2018
accepted:
27
04
2018
pubmed:
19
7
2018
medline:
4
6
2020
entrez:
19
7
2018
Statut:
ppublish
Résumé
The incidence of colorectal cancer (CRC) in younger patients is rising, mostly due to tumors in the descending colon and rectum. Therefore, we aimed to explore the molecular differences of left-sided CRC between younger (≤45 years) and older patients (≥65). In total, 1,126 CRC tumor samples from the splenic flexure to (and including) the rectum were examined by next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization. Microsatellite instability (MSI) and tumor mutational burden (TMB) were assessed by NGS. Younger patients ( Our findings highlight the importance of genetic counseling and screening in younger CRC patients. MSI-H and TMB-high tumors could benefit from immune-checkpoint inhibitors, now approved for the treatment of MSI-H/deficient mismatch repair metastatic CRC patients. Finally, histone modifiers could serve as a new promising therapeutic target. With confirmatory studies, these results may influence our approach to younger adults with CRC. The increasing rate of colorectal cancers (CRC), primarily distal tumors, among young adults poses a global health issue. This study investigates the molecular differences between younger (≤45 years old) and older (≥65) adults with left-sided CRCs. Younger patients more frequently harbor mutations in genes associated with cancer-predisposing syndromes. Higher rates of microsatellite instability-high and tumor mutational burden-high tumors occur in younger patients, who could benefit from immune-checkpoint inhibitors. Finally, histone modifiers are more frequently mutated in younger patients and could serve as a new promising therapeutic target. This study provides new insights into mutations that may guide development of novel tailored therapy in younger CRC patients.
Sections du résumé
BACKGROUND
The incidence of colorectal cancer (CRC) in younger patients is rising, mostly due to tumors in the descending colon and rectum. Therefore, we aimed to explore the molecular differences of left-sided CRC between younger (≤45 years) and older patients (≥65).
SUBJECTS, MATERIALS, AND METHODS
In total, 1,126 CRC tumor samples from the splenic flexure to (and including) the rectum were examined by next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization. Microsatellite instability (MSI) and tumor mutational burden (TMB) were assessed by NGS.
RESULTS
Younger patients (
CONCLUSION
Our findings highlight the importance of genetic counseling and screening in younger CRC patients. MSI-H and TMB-high tumors could benefit from immune-checkpoint inhibitors, now approved for the treatment of MSI-H/deficient mismatch repair metastatic CRC patients. Finally, histone modifiers could serve as a new promising therapeutic target. With confirmatory studies, these results may influence our approach to younger adults with CRC.
IMPLICATIONS FOR PRACTICE
The increasing rate of colorectal cancers (CRC), primarily distal tumors, among young adults poses a global health issue. This study investigates the molecular differences between younger (≤45 years old) and older (≥65) adults with left-sided CRCs. Younger patients more frequently harbor mutations in genes associated with cancer-predisposing syndromes. Higher rates of microsatellite instability-high and tumor mutational burden-high tumors occur in younger patients, who could benefit from immune-checkpoint inhibitors. Finally, histone modifiers are more frequently mutated in younger patients and could serve as a new promising therapeutic target. This study provides new insights into mutations that may guide development of novel tailored therapy in younger CRC patients.
Identifiants
pubmed: 30018131
pii: theoncologist.2018-0117
doi: 10.1634/theoncologist.2018-0117
pmc: PMC6519749
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-326Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Therap Adv Gastroenterol. 2017 Jan;10(1):114-131
pubmed: 28286564
J Clin Oncol. 2016 Jun 20;34(18):2141-7
pubmed: 27022117
Medicine (Baltimore). 2015 Sep;94(35):e1402
pubmed: 26334895
Annu Rev Microbiol. 2016 Sep 8;70:395-411
pubmed: 27607555
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
World J Gastroenterol. 2016 Feb 7;22(5):1736-44
pubmed: 26855533
Cancer. 2016 Mar 15;122(6):929-34
pubmed: 26808454
JAMA Oncol. 2017 Feb 01;3(2):211-219
pubmed: 27787550
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Gastroenterol Res Pract. 2015;2015:132190
pubmed: 26557847
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
Eur J Cancer. 2015 Jul;51(11):1405-14
pubmed: 25979833
J Pathol. 2013 Jun;230(2):148-53
pubmed: 23447401
Int J Biochem Cell Biol. 2012 Aug;44(8):1276-89
pubmed: 22583735
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
JAMA Oncol. 2017 Apr 01;3(4):464-471
pubmed: 27978560
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Cancer. 2016 Sep 15;122(18):2828-35
pubmed: 27244218
Oncology (Williston Park). 2017 May 15;31(5):381-9
pubmed: 28516436
PLoS One. 2012;7(9):e45357
pubmed: 23049789
Isr Med Assoc J. 2013 Jun;15(6):284-7
pubmed: 23882892
J Pediatr Surg. 2016 Nov;51(11):1812-1817
pubmed: 27558481
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216
pubmed: 28404093
World J Gastroenterol. 2014 Sep 21;20(35):12420-30
pubmed: 25253942
Mayo Clin Proc. 2014 Feb;89(2):216-24
pubmed: 24393412
PLoS One. 2014 Jul 08;9(7):e102004
pubmed: 25003760
Oncotarget. 2017 Sep 21;8(49):86356-86368
pubmed: 29156800
Clin Colorectal Cancer. 2016 Mar;15(1):32-6
pubmed: 26341410
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
N Engl J Med. 2000 Jan 13;342(2):69-77
pubmed: 10631274
World J Gastroenterol. 2014 Dec 14;20(46):17288-96
pubmed: 25516639
Int J Cancer. 2002 Apr 20;98(6):844-50
pubmed: 11948461
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
JAMA Oncol. 2017 Feb 01;3(2):194-201
pubmed: 27722750
Curr Treat Options Oncol. 2015 Jul;16(7):30
pubmed: 26031544
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Mol Cancer Res. 2018 May;16(5):805-812
pubmed: 29523759
Clin Gastroenterol Hepatol. 2010 Nov;8(11):966-71
pubmed: 20655395